Abstract
Therapeutic recombinant glycoproteins are important for both the biotechnological industry and clinical purposes. Given the rapid clearance of these proteins from the circulation, they have to be injected frequently to obtain optimal therapy. Several strategies have been developed to overcome this limitation, aiming to increase the half-life of such proteins in the circulation. These strategies included chemical attachment of polyethylene glycol, nanocapsulation, fusion to immunoglobulins or to albumin as protein carriers, or enrichment of the carbohydrate content. Here, we describe a strategy for increasing the half-life of recombinant proteins using gene fusion to increase the carbohydrate content of the protein backbone.
Original language | English |
---|---|
Pages (from-to) | 1017-1022 |
Number of pages | 6 |
Journal | Drug Discovery Today |
Volume | 24 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2019 |
Bibliographical note
Publisher Copyright:© 2019 Elsevier Ltd
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery